Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human neutrophil antigens (HNA) represent a diverse group of glycoproteins expressed on the surface of neutrophils that are polymorphic within the human population. These antigens are categorized into five distinct systems (HNA-1 through HNA-5) based on the specific proteins they reside upon, such as Fc gamma receptor IIIb (CD16b), CD177, and various integrins. While they serve physiological roles in immune cell adhesion and signaling, their primary clinical significance lies in their role as targets for alloantibodies. These antibodies can trigger serious adverse reactions, including transfusion-related acute lung injury (TRALI) and neonatal alloimmune neutropenia (NAN). Because the term refers to a collective group of distinct proteins rather than a single molecular entity, it is generally classified as a category of biomarkers or clinical triggers rather than a specific therapeutic drug target.
Not applicable as this is a broad category of antigens rather than a single drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human neutrophil antigen (HNA).